Labetuzumab Govitecan provides an antibody-drug conjugate (ADC) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and specifically combines a CEACAM5-directed monoclonal antibody with the topoisomerase I inhibitor payload SN-38 for ADC and oncology research.
Key Features and Benefits
- Antibody-Drug Conjugate: Combines a CEACAM5-targeting monoclonal antibody specifically with the cytotoxic payload SN-38.
- CEACAM5 Targeting: Supports research involving CEACAM5 expression, antibody binding, internalization, and targeted delivery.
- SN-38 Payload: Incorporates SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor.
- Targeted Payload Delivery: Supports investigation of antibody-mediated SN-38 delivery to CEACAM5-expressing cells.
- Cleavable Linker System: Enables research into linker stability, intracellular payload release, and ADC activity.
- ADC Research Platform: Supports studies of target engagement, cellular uptake, payload effects, and ADC mechanisms.
- Oncology Research: Especially useful for investigating CEACAM5 biology and targeted ADC strategies in cancer research models.
Applications
- ADC Research: Supports studies of antibody-drug conjugate targeting, internalization, and payload delivery.
- CEACAM5 Research: Useful for investigating CEACAM5 expression, function, and antibody-mediated targeting.
- Cancer Biology Research: Supports studies specifically involving CEACAM5-expressing cancer models and related cellular pathways.
- Targeted Drug Delivery: Especially useful for investigating antibody-mediated delivery of SN-38.
- Cell-Based Assays: Supports evaluation of binding, internalization, cellular response, and ADC activity.
- Mechanism-of-Action Studies: Useful for studying CEACAM5 targeting and SN-38-mediated topoisomerase I inhibition.
- Comparative ADC Research: Supports evaluation of ADC designs, targeting strategies, linkers, and payload performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Labetuzumab Govitecan combines CEACAM5-directed antibody targeting with an SN-38 payload and specifically supports ADC research, CEACAM5 studies, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
